Dupilumab Reduces Itch and Sleep Loss over 3 Years in Patients 6 Months to 11 Years with Severe Atopic Dermatitis

Background: Sleep disturbance is common in young children with atopic dermatitis (AD), often driven by night-time itch, and reduces quality of life for patients and caregivers. Dupilumab has improved sleep and itch for up to 1 year in pediatric patients with AD. We report dupilumab impact on sleep and itch over 3 years in children aged 6 months to 11 years with severe AD.

Methods: Children, 6 months to 11 years, with severe AD (Investigator’s Global Assessment score = 4) from prior placebo-controlled dupilumab studies (NCT03346434, NCT03345914) entered an open-label extension study (OLE; NCT02612454). OLE dosing was weight-based: 200 mg every 4 weeks (q4w; 5–<15 kg), 300 mg q4w (15–<30 kg), 200 mg every 2 weeks (q2w; 30–<60 kg), or 300 mg q2w (≥60 kg). Topical treatments were allowed. Patient disposition and mean percent change in SCORing Atopic Dermatitis (SCORAD) Sleep Loss (0–10) and Pruritus (0–10) visual analog scale scores were assessed from parent study baseline through OLE Week 152.

Results: 125 children entered the OLE; 36 discontinued by Week 152. Mean (SD) treatment exposure was 158.9 (84.8) weeks. In the prior-placebo group, mean percent change from baseline in SCORAD Sleep Loss was +54.8% at parent study Week 16, and improved to −58.3% at OLE Week 152 after dupilumab exposure. Children on dupilumab in the parent study showed sleep loss reductions of −65.8% at Week 16 and −73.7% at Week 152. SCORAD Pruritus improved from −13.8% at Week 16 to −66.2% at Week 152 in prior-placebo recipients, and was −63.8% at Week 16 and −71.0% at Week 152 in prior-dupilumab recipients. Safety was consistent with the known dupilumab profile.

Conclusions: Dupilumab treatment provided sustained, long-term improvement in sleep loss and itch over 3 years in children aged 6 months to 11 years with severe AD.